Cancer Archives

News and Trends 25 Aug 2022

Zelluna Immunotherapy announces investment from Takeda Ventures, Inc.

Zelluna Immunotherapy, a company focused on allogenic T-cell Receptor Natural Killer (TCR-NK) cells to treat cancer has today (August 25) announced an investment from Takeda Ventures, Inc. (TVI), the strategic arm of Takeda. TVI investment joins Zelluna’s latest financing round. The funds will enable the advancement of a lead TCR-NK product through manufacturing to Clinical […]

August 25, 2022 - 2 minutesmins - By Liza Laws

News and Trends 24 Aug 2022

Gene therapies for lung cancer identified by international team of scientists

Gene therapies for lung cancer can be found by CRISPR genome editing technology, an international team of scientists have discovered. CRISPR genome-editing is a powerful tool that gives scientists a cheap and easy way to find and alter a specific piece of DNA within a cell – the ‘cut and paste’ of the biological world. […]

August 24, 2022 - 2 minutesmins - By Liza Laws

News and Trends 24 Aug 2022

Study findings could lead to new anti-cancer drugs

German scientists say a drug already approved for other purposes can negate how tumor cells protect themselves from the immune system. Many tumor cells mist themselves with a protective ‘perfume’ that disables the immune system. But a drug already approved for other purposes can apparently render this weapon harmless. This is the conclusion of a […]

August 24, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 24 Aug 2022

Potential new treatment for angioimmunoblastic T-cell lymphoma?

A type of blood cell cancer called angioimmunoblastic T-cell lymphoma (AITL) can develop as mutations accumulate with age in the stem cells from which the T cells in the blood develop. However, the underlying mechanism by which AITL develops was unknown. Now, a team from the University of Tsukuba in Japan have shown that B […]

August 24, 2022 - 3 minutesmins - By Jim Cornall

In Depth 24 Aug 2022

To reach Mars, we need biotechnology

As we prepare for long-distance space travel and life on Mars, biotechnology will be essential to make spaceships no longer dependent on Earth’s constant supply. “As human beings, we need a constant supply of oxygen. We need constant access to nutritious food, clean water and a safe and clean waste disposal system,” says Italian astronaut […]

August 24, 2022 - 11 minutesmins - By Clara Rodríguez Fernández

News and Trends 24 Aug 2022

Oncolyze seeking investment for AML clinical trials

After successfully completing in vitro and in vivo experiments, which support the notion that its lead drug candidate OM-301 breaks down cancer cells and increases survival rates, Oncolyze now has its sights set on advancing OM-301 into clinical trials. Oncolyze has launched a Regulation A+ funding campaign to spread awareness of OM-301 among cancer patients, […]

August 24, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 24 Aug 2022

Northwest Biotherapeutics’ pediatric investigation plan approved by MHRA

Northwest Biotherapeutics, a biotech company developing DCVax personalized immune therapies for solid tumor cancers, has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for its pediatric investigation plan (PIP). The development, regulatory review and regulatory approval of a PIP is a pre-requisite for application for approval of a new medicine for […]

August 24, 2022 - 3 minutesmins - By Jim Cornall

Cytimmune Sciences nanoparticles red recognizing entering and accumulating in cancer cells

News and Trends 23 Aug 2022

Novel nanotechnology ‘supercharges’ immune system molecules to fight cancer

Researchers from Cytimmune Sciences, a clinical-stage biotech company, have presented new data on the company’s novel cancer nanomedicines. The presentation took place at the Cytokine Drug Development Conference held in Boston, Massachusetts, late last month. David Oarr, Cytimmune’s president, participated in the event’s opening panel to discuss the current clinical status and future anticipated progress […]

August 23, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 19 Aug 2022

Emtora to use $16.9M grant to develop treatment for rare genetic disease

Emtora Biosciences, a Texas-based clinical-stage biopharmaceutical company, has been awarded a $16.9 million non-dilutive grant from the Cancer Prevention & Research Institute of Texas (CPRIT). The funding will be used to advance the clinical and product development of its lead program, eRapa, an encapsulated form of rapamycin, for the treatment of familial adenomatous polyposis (FAP). […]

August 19, 2022 - 2 minutesmins - By Jim Cornall

Kintor Pharmaceutical drug gets positive results for breast cancer

News and Trends 19 Aug 2022

Gilead to acquire remaining worldwide rights of breast cancer drug, Trodelvy

All of Everest Medicine’s development and commercialization rights for a breast cancer drug called Trodelvy have been transferred to American biopharma Gilead Sciences Inc. The transfer of the antibody drug, sacituzumab govitecan treatment, will apply to Greater China, South Korea, Singapore, Indonesia, Philippines, Vietnam, Thailand, Malaysia and Mongolia. In China mainland and Singapore, Trodelvy is […]

August 19, 2022 - 3 minutesmins - By Liza Laws

News and Trends 18 Aug 2022

First patient on Innovative Cellular Therapeutics’ study looking at treating colorectal cancer

The first patient has been enrolled on a study to trial a treatment for relapsed or refractory metastatic colorectal cancer (R/R mCRC) in the U.S. Innovative Cellular Therapeutics (ICT), Inc. a clinical-stage biotechnology company developing a comprehensive portfolio of chimeric antigen receptor (CAR) T cell therapies made the announcement today (August 18). Tolerability The study […]

August 18, 2022 - 2 minutesmins - By Liza Laws

News and Trends 18 Aug 2022

FDA lifts partial clinical hold on Curis lymphoma study

Curis, Inc., a biotech company focused on the development of innovative therapeutics for the treatment of cancer, says the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the TakeAim lymphoma phase 1/2 study of emavusertib after reviewing the data package submitted by Curis. “We are excited to announce that FDA […]

August 18, 2022 - 4 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

Zelluna Immunotherapy announces investment from Takeda Ventures, Inc.

Gene therapies for lung cancer identified by international team of scientists

Study findings could lead to new anti-cancer drugs

Potential new treatment for angioimmunoblastic T-cell lymphoma?

To reach Mars, we need biotechnology

Oncolyze seeking investment for AML clinical trials

Northwest Biotherapeutics’ pediatric investigation plan approved by MHRA

Novel nanotechnology ‘supercharges’ immune system molecules to fight cancer

Emtora to use $16.9M grant to develop treatment for rare genetic disease

Gilead to acquire remaining worldwide rights of breast cancer drug, Trodelvy

First patient on Innovative Cellular Therapeutics’ study looking at treating colorectal cancer

FDA lifts partial clinical hold on Curis lymphoma study

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!